Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.77 |
| ▸ | PPARG | P37231 | 3/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.77 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | PCNA | P12004 | 2/20 | 0.73 |
| ▸ | TAAR5 | O14804 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | THRA | P10827 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | GABRP | O00591 | 1/20 | 0.56 |
| ▸ | GABRD | O14764 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8329881 | 1.00 | MEN1 (0.77) | MEN1KMT2APPARGNR1I2AGTR2 | |
| SCHEMBL30114468 | 1.00 | MEN1 (0.77) | MEN1KMT2APPARGNR1I2AGTR2 | |
| SCHEMBL29397778 | 1.00 | MEN1 (0.77) | MEN1KMT2APPARGNR1I2AGTR2 | |
| SCHEMBL1170097 | 1.00 | MEN1 (0.77) | MEN1KMT2APPARGNR1I2AGTR2 | |
| SCHEMBL28502877 | 0.88 | SLC7A5 (0.62) | MEN1KMT2APPARGNR1I2AGTR2 | |
| SCHEMBL28502876 | 0.88 | SLC7A5 (0.62) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Diiodothyronine SCHEMBL677645 | 0.88 | MEN1 (0.78) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Diiodothyronine SCHEMBL31613058 | 0.88 | MEN1 (0.78) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Diiodothyronine SCHEMBL29374527 | 0.88 | MEN1 (0.78) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Diiodothyronine SCHEMBL29410661 | 0.88 | MEN1 (0.78) | MEN1KMT2APPARGNR1I2AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114609266-B | Application of marker in preparation of diagnostic reagent for thyroid related diseases | 徐州医科大学 | 2023-03-24 | — | — | CN | claimed |
| CN-114609265-B | Method for detecting eight thyroid hormone markers in serum by liquid chromatography tandem mass spectrometry technology | 徐州医科大学 | 2023-01-24 | — | — | CN | claimed |
| CN-114609265-A | Method for detecting eight thyroid hormone markers in serum by liquid chromatography tandem mass spectrometry technology | 徐州医科大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114609266-A | Application of marker in preparation of diagnostic reagent for thyroid related diseases | 徐州医科大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114540303-A | Limbal stem cell culture solution and preparation method thereof | 赛尔生命科技(深圳)有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-113645850-A | Methods of modulating gastrointestinal metabolites | 帝斯曼知识产权资产管理有限公司 | 2021-11-12 | — | — | CN | claimed |
| CN-111467302-A | Injectable temperature-sensitive refrigeration hydrogel capable of inducing local sub-low temperature to treat craniocerebral trauma | 徐州医科大学 | 2020-07-31 | — | — | CN | claimed |
| US-20200222348-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | MUSLI THYROPEUTICS LTD. (IL) | 2020-07-16 | — | — | US | claimed |
| US-20110064773-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | UNIVERSITE JOSEPH FOURIER (FR) | 2011-03-17 | — | — | US | claimed |
| US-20110028554-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE | UNIVERSITE JOSEPH FOURIER (FR) | 2011-02-03 | — | — | US | claimed |
| EP-2068859-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | Université Joseph Fourier (FR) | 2009-06-17 | — | — | EP | claimed |
| EP-2068858-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE | Université Joseph Fourier (FR) | 2009-06-17 | — | — | EP | claimed |
| WO-2008138995-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | UNIVERSITE JOSEPH FOURIER (FR) | 2008-11-20 | — | — | WO | claimed |
| WO-2008138993-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE | UNIVERSITE JOSEPH FOURIER (FR) | 2008-11-20 | — | — | WO | claimed |
| EP-1992341-A1 | New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use | Université Joseph Fourier (FR) | 2008-11-19 | — | — | EP | claimed |
| US-20040116391-A1 | Stabilized thyroxine compounds | NEW RIVER PHARMACEUTICALS INC. | 2004-06-17 | — | — | US | claimed |
| EP-0093653-B1 | PROCESS FOR THE PREPARATION OF IODO-THYRONINES AND IODO-THYROACETIC ACIDS BY ELECTROCHEMICAL REDUCTION AT A CONTROLLED POTENTIAL | SPIRAL Société à responsabilité limitée dite : (FR) | 1985-07-10 | — | — | EP | claimed |
| US-4490221-A | Process for preparing iodothyronines and iodothyroacetic acids by electrochemical reduction at controlled potential | SPIRAL SOCIETE A RESPONSABILITE LIMITEE DITE (FR) | 1984-12-25 | — | — | US | claimed |
| CN-121868277-A | Application of SLCO5A1 in preparation of medicines for treating and/or preventing heart failure | 广东医科大学附属第二医院 | 2026-04-17 | — | — | CN | disclosed |
| US-4360358-A | Immunoassay with solid phase having coating containing blood platelet substitute | PANBAXY LABORATORIES INTERNATIONAL CORPORATION | 1982-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028554-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE | TPO, HSD3B2, THRB | MEN1 692/4885KMT2A 2483/4885PPARG 189/4885 |
| US-20110064773-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE | TPO, TSHR, THRA | MEN1 301/4885KMT2A 4327/4885PPARG 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.